Evidence map›Paper›PMID 36551381›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Biocide-Resistant

Srinivasan Vijaya Bharathi, Govindan Rajamohan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Srinivasan Vijaya BharathiBacterial Signaling and Drug Resistance Laboratory, Council of Scientific and Industrial Research-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
Govindan RajamohanBacterial Signaling and Drug Resistance Laboratory, Council of Scientific and Industrial Research-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
Institute of Microbial Technology · IN

Funding

Indian Council of Medical Research 2020-3673
6 · The paper itself

Abstract

Emerging sequence types of pathogenic bacteria have a dual ability to acquire resistance islands/determinants, and remain renitent towards disinfection practices; therefore, they are considered "critical risk factors" that contribute significantly to the global problem of antimicrobial resistance. Multidrug-resistant

Indexed as

active effluxcommensal bacteriadrug resistomemembrane transportersouter membrane proteinsreservoirs

Identifiers

PMID36551381
PMCPMC9774513
OpenAlexW4311013881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.